Who are ARRY-502, CRTh2 antagonist; oral's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arry-502-crth2-antagonist-oral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ARRY-502, CRTh2 antagonist; oral — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ARRY-502, CRTh2 antagonist; oral (ARRY-502, CRTh2 antagonist; oral) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CRTh2 antagonist. Area: Immunology.

phase 2 CRTh2 antagonist CRTh2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ARRY-502, CRTh2 antagonist; oral (ARRY-502, CRTh2 antagonist; oral) — Pfizer. Blocks CRTh2 receptor to reduce inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARRY-502, CRTh2 antagonist; oral TARGET	ARRY-502, CRTh2 antagonist; oral	Pfizer	phase 2	CRTh2 antagonist	CRTh2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CRTh2 antagonist class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARRY-502, CRTh2 antagonist; oral — Competitive Intelligence Brief. https://druglandscape.com/ci/arry-502-crth2-antagonist-oral. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab